1. Nagen Technology (09856.HK): Plans to issue 172 million H shares in its Hong Kong listing at HK$32.96 per share.
2. R&F Properties (02777.HK): Total sales revenue for the first eight months was approximately RMB 8.85 billion, a decrease of 5.85% year-on-year.
3. Hengrui Medicine (01276.HK): Its injectable drug, Ruzetatopramab, has been included in the Breakthrough Therapy Product List.
4. Zhongliang Holdings (02772.HK): Cumulative contracted sales for the first eight months were approximately RMB 4.29 billion, a decrease of 48.25% year-on-year.
5. Seazen Holdings (01030.HK): Cumulative contracted sales for the first eight months were approximately RMB 8.107 billion, a decrease of 40.24% year-on-year.
6. Global Digital Holdings (00339.HK): Plans to place up to 86.4 million shares at a discount of approximately 18.25%, raising net proceeds of approximately HK$46.76 million.
7. China Biopharmaceutical (01177.HK) plans to acquire a 5% stake in Chia Tai Tianqing Pharmaceutical Group from Xie Chengrun for RMB 4.48 billion, increasing its indirect shareholding to 65% upon completion.
8. Hansoh Pharmaceutical (03692.HK): Its injectable levotartrazine (HS-20093) for the treatment of small cell lung cancer has been included in the priority review and approval process of the National Medical Products Administration.
